Akademik Veri Yönetim Sistemi
SAĞLIKTA GÜNCEL GELİŞMELER IŞIĞINDA TEMEL ve KLİNİK YAKLAŞIMLAR-II, Özge Gülmez,Buruç Erkan,Emir Kaan İzci, Editör, Ekin Yayınevi, Bursa, ss.133-162, 2022
Lipid-based formulations (LBFs) have been used for oral administration for many years to enhance the absorption of lipophilic drugs, poorly water-soluble drugs (Lafountaine et al., 2016). Poorly water-soluble drugs these days are increasingly discovered, hence like this issue the need for the lipid-based formulation is growing (Kilic et al., 2019) (Ghadi & Dand, 2017). LBFs introduce dissolution rate limited drugs in a pre-solubilized form to be ready for absorption in the gastrointestinal tract, on other hand, solubility-limited drugs via several mechanisms for enhanced absorption (Lafountaine et al., 2016). Lipids as vehicles have the possibility of providing unlimited opportunities in drug delivery as a result of them being able to increase gastrointestinal solubilization along with absorption via selective lymphatic uptake of low bioavailability drugs (Ghadi & Dand, 2017). In addition, to release amphiphilic lipid digest products, lipids are hydrolyzed via gastric and pancreatic enzymes, leading to being solubilized by biliary secretion (McEvoy et al., 2017). Partition coefficient (log P) plays an essential role in formulation development for oral drug delivery and is a crucial physicochemical property of lipophilic drugs. An ideal drug candidate for a lipid-based formulation is highly lipophilic drugs (log P > 5) (Patel et al., 2018a) (Carrière, 2016). The Food and Drug Administration (FDA) approved some LBFs such as Drisdol in 1941 (type I), Sandimmune in 1983 (Type II), Neoral in 1995 (type III), and Agenerase in 1999 (type IV) (Huang et al., 2021), as well as the successful products of Sandimmun Neoral (cyclosporin A), Norvir (ritonavir), and Fortovase (saquinavir), encouraged further attention in this technology (Xia et al., 2021).